STAT3 and glioblastoma: All these suggested that upregulation of the STAT3 pathway can mediate resistance of GBM cells to anti-angiogenic therapy, while the combination of STAT3 inhibitor and anti-vascular therapy inhibitor can delay or reduce the resistance to the anti-angiogenic therapy.